Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
In the phase 2 SEISMiC trial, istaroxime met its primary endpoint of improving systolic BP profile at 6 hours in patients with cardiogenic shock, according to the topline results announced by Windtree Therapeutics.
“These results are very exciting and indicate that istaroxime has the potential to become a novel approach to patient care that fills an important gap in treating cardiogenic
Tenaya Therapeutics : Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.